FAPXIL

About TherapyX

TherapyX is pioneering a novel drug delivery platform, EXStaM, designed to encapsulate and deliver large biologic molecules orally and via other routes while preserving their full biological activity. Its pipeline includes several preclinical and early-stage programs targeting pancreatic cancer, gonorrhea, and Familial Adenomatous Polyposis (FAP), with one program having received FDA Orphan Drug Designation. Founded in 2016 by academic scientists, the company is privately held, pre-revenue, and has secured non-dilutive funding from grants, including a recent $3 million NIH award.

Therapeutic Areas

Other Familial Adenomatous Polyposis Drugs